Clinical trial
Melatonin Effects on Sleep and Circadian Rhythm in Youth and Young Adults With At-risk Symptoms
Name
18-014932
Description
Randomized control trial assessing supplemental melatonin for youth with at-risk or psychotic symptoms.
Trial arms
Trial start
2019-01-18
Estimated PCD
2023-04-07
Trial end
2023-04-07
Status
Completed
Treatment
oral melatonin tablets (NatureMade brand)
melatonin tablets
Arms:
Melatonin
Placebo
pill placebo
Arms:
Placebo
Size
21
Primary endpoint
Actigraph-measured sleep (increased total sleep time)
Change in total sleep time from melatonin randomization day (Day 0) to Day 14
Eligibility criteria
Inclusion Criteria:
* Males or females age 11-30 years old and patient at the Children's Hospital of Philadelphia (CHOP), University of Pennsylvania (UPenn), or member of the surrounding community
* Subthreshold psychosis-risk positive symptoms (e.g. hallucinations or unusual beliefs) on the Structured Interview of Psychosis-Risk Syndromes (SIPS)
* At least mild sleep disturbances on the SIPS (\>=1 on the SIPS sleep item (G1)) with difficulties with
* Must have difficulties with sleep onset, sleep awakenings, or maintaining a regular sleep schedule.
* Willingness to report all changes in medications and therapy during the study
* Intelligence Quotient (IQ) \> 70
* If female, not breastfeeding and not pregnant and willing to use effective birth control for the duration of the study (e.g. abstinence or oral contraception).
* Medically healthy
* Fluent in English
Exclusion Criteria:
* Psychiatric symptoms with imminent safety concern (e.g. intractable and escalating suicidal ideation)
* Currently taking melatonin, having taken melatonin daily within the 2 weeks prior to Visit 1, or having a history of an intolerance or allergy to melatonin.
* Medication or treatment changes in the 4 weeks prior to Visit 1 .
* Anticipated medication or other treatment (e.g. type of psychotherapy) changes in the three weeks after study enrollment.
* IQ \<70
* Taking any medication whose potential interactions with melatonin present a significant risk or limit the effect of melatonin in the judgment of the investigators.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'OTHER', 'maskingInfo': {'masking': 'QUADRUPLE', 'maskingDescription': 'Only the pharmacy will know the randomization arms.', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 21, 'type': 'ACTUAL'}}
Updated at
2023-05-09
1 organization
1 product
2 indications
Organization
Children's Hospital of PhiladelphiaProduct
MelatoninIndication
PsychosisIndication
Insomnia